Abstract
The neonate born to a myasthenic mother can be affected by transient neonatal myasthenia gravis (NMG). The patients with severe symptoms are usually treated with cholinesterase inhibitors, which have potential cardiovascular effects. Recently, intravenous immunoglobulin (IVIG) has been reported as an effective and safe choice in the treatment of myasthenia gravis (MG). We have used IVIG (0.4 g/kg/day for 5 days) in the prophylaxis of NMG in a neonate born to a myasthenic mother. The baby showed no myasthenic symptoms during the follow-up (10 days), and no side effects were observed.
Get full access to this article
View all access options for this article.